Received Jun 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 1 | — | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 2 | Y015100 | — |
No side effects or symptoms reported; HCP called to report a 25-year-old patient received their first does of VARIVAX in 2018 (exact date unknown, lot and exp date unknown) and did not receive their second dose until 06/03/2025. No side effects or symptoms reported. No Additional AE/ No; This spontaneous report was received from a pharmacist and refers to a 25-year-old female patient. The patient's medical history, concurrent conditions, and concomitant therapies were not reported. In 2018, the patient was vaccinated with the first dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) as prophylaxis (dose, route of administration, anatomical location, lot # and expiration date were not reported). Then on 03-JUN-2025, the patient was vaccinated with the second dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) at a dose of 0.5 mL as prophylaxis (valid lot #Y015100, expiration date: 06-SEP-2026) (inappropriate schedule of product administration). Both reconstituted with sterile diluent (dose, lot number, anatomical location, and indication were not provided). No side effects or symptoms reported (no adverse event). Lot # is being requested and will be submitted if received (dose #1)
Sterile diluent